For sales

Highlights from the Week of 11th May – 18th May in the world of pharma and healthcare!

Highlights from the week of 11th May - 18th May Fosun Pharma ( Collaboration ) Fosun Pharma and AriBio sign an exclusive global agreement for the development, registration, manufacturing and commercialization of AR1001, a phosphodiesterase-5 inhibitor with disease-modifying potential to treat AD Alkermes ( Phase 3, Results ) Phase 3 REVITALYZ study of Alkermes evaluating LUMRYZ extended-release oral suspension in adults with idiopathic hypersomnia demonstrates significant improvements in excessive daytime sleepiness compared to placebo AstraZeneca ( Phase 3, Results ) AstraZeneca's VOLGA Phase 3 trial evaluating IMFINZI in combination with neoadjuvant enfortumab vedotin demonstrates clinically meaningful improvements in EFS and OS in muscle-invasive bladder cancer AstraZeneca ( Phase 3, Results ) The CALYPSO Phase 3 trial from AstraZeneca assessing AZP-3601 demonstrates clinically meaningful normalization of sCa levels and independence from active vitamin D and oral calcium supplements in adults with chronic HypoPT at week 24 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.